CPC-211 (Questcor).
CPC-211 is under development by Questcor (formerly Cypros) as a potential treatment for stroke and closed head injury. Phase II trials have commenced for both indications. In June 1999, it was granted Orphan Drug status [329979]. In July 1998, CPC-211 received expedited development status by the FDA, following a review of the company's data and clinical plan for the development of CPC-211 to treat acute head injury [291130]. CPC-211 stimulates the action of pyruvate dehydrogenase, reducing the build up of lactic acid which may cause brain damage after stroke. It diverts the lactate production into acetyl-CoA which is a beneficial metabolite. CPC-211 crosses the blood-brain barrier. Preclinical studies involving both stroke and head injury models have shown that CPC-211 (25 to 200 mg/kg iv) effected a significant reduction in brain lactate levels [328231].
Thatte
U
U
Department of Pharmacology and Therapeutics, Seth GS Medical College, Parel, Mumbai 400 012, India. mthatte@bom5.vsnl.net.in